Bracing For The Cold: Time For Korean Bioventures To Cut Down

Select And Focus Strategy Recommended

A recent forum in South Korea heard from a venture capital executive about the changing IPO and financing environment and how bioventures might be able to cope with these changes.

Gi Soo Kang, Partner, BNH Investment
Korean Firms Should Consider Various Funding Options

Investors have been flocking to the worldwide biotech sector over the past few years amid high returns and as a result initial public offerings in the sector have also attracted strong interest. But sentiment has now begun to change from last year amid the broader stock market weakness globally.

More from South Korea

More from Focus On Asia